Table 3.

Comparison of outcomes of combined hepatic and pancreatic resection for PCLM and palliative therapies.

Reference	No-resection		Resection		Significance
	Patient number	mOS (months)	Patient number	mOS (months)	p-value
Positive studies
Shrikhande et al.13	118	5.9	11	11.4	0.04
Tachezy et al.5	69	8	69	14	<0.01
Crippa et al.14	116	11	11	39	<0.0001
Other studies
Gleisner et al.15	66	5.6	22	5.9	0.46
Seelig et al.16	20	15.6	20	10.7	0.11
Yang et al.17	31	7.6	48	7.8	0.37
Yamada et al.18	28	6.8	11	10.1	NS
Takada et al.19	22	3	11	6	NR
Duenschede et al.6	5	11	8	9	NR

mOS, median overall survival; PCLM, Pancreatic ductal adenocarcinoma with liver metastases.